{"transactions":[{"id":1772041,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-09-28T20:52:27.000Z","date":"2023-09-26","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a 12 month period: 1/12th on October 26, 2023, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":10000,"derivative":{"exercise_price":10.08,"expiration_date":"2033-09-25","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-23-050750","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000120919123050750/doc4.xml","form_type":"4"}},{"id":1781861,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-13T20:29:52.000Z","date":"2023-09-11","kind":"exercise","planned":false,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.88,"expiration_date":"2027-03-22","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-23-049268","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000120919123049268/doc4.xml","form_type":"4"}},{"id":1781860,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-13T20:29:52.000Z","date":"2023-09-11","kind":"exercise","planned":false,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.71,"expiration_date":"2027-09-27","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-23-049268","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000120919123049268/doc4.xml","form_type":"4"}},{"id":1781859,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-13T20:29:52.000Z","date":"2023-09-11","kind":"sale","planned":false,"acquired":false,"shares":18000,"price":10.5028,"value":189050.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-049268","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000120919123049268/doc4.xml","form_type":"4"}},{"id":1781858,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-13T20:29:52.000Z","date":"2023-09-11","kind":"exercise","planned":false,"acquired":true,"shares":12000,"price":7.88,"value":94560.0,"ownership":{"direct":true},"balance_after":18000,"source":{"system":"sec-edgar","filing":"0001209191-23-049268","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000120919123049268/doc4.xml","form_type":"4"}},{"id":1781857,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-13T20:29:52.000Z","date":"2023-09-11","kind":"exercise","planned":false,"acquired":true,"shares":6000,"price":6.71,"value":40260.0,"ownership":{"direct":true},"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001209191-23-049268","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000120919123049268/doc4.xml","form_type":"4"}},{"id":2136215,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-10-17T22:34:53.000Z","date":"2022-10-13","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a 12 month period: 1/12th on October 13, 2022, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":10000,"derivative":{"exercise_price":4.53,"expiration_date":"2032-10-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-22-053875","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000120919122053875/doc4.xml","form_type":"4"}},{"id":2554029,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-10-01T20:53:10.000Z","date":"2021-09-30","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a 12 month period: 1/12th on October 30, 2021, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":10000,"derivative":{"exercise_price":17.45,"expiration_date":"2031-09-29","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-058484","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000120919121058484/doc4.xml","form_type":"4"}},{"id":2994360,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-04T00:56:48.000Z","date":"2020-10-30","kind":"purchase","acquired":true,"shares":47431,"price":17.3359,"value":822259.0729,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.26 to $17.35 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Opportunity Fund, L.P. The general partner of the holder is Vivo Opportunity, LLC, of which the Reporting Person is a voting member. The Reporting Person may be deemed to share voting and dispositive power over these shares with four (4) other voting members. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes."}],"balance_after":1138179,"source":{"system":"sec-edgar","filing":"0001209191-20-056790","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000120919120056790/doc4.xml","form_type":"4"}},{"id":2994359,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-04T00:56:48.000Z","date":"2020-10-30","kind":"purchase","acquired":true,"shares":68255,"price":17.1681,"value":1171808.6655,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.26 to $17.25 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Opportunity Fund, L.P. The general partner of the holder is Vivo Opportunity, LLC, of which the Reporting Person is a voting member. The Reporting Person may be deemed to share voting and dispositive power over these shares with four (4) other voting members. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes."}],"balance_after":1090748,"source":{"system":"sec-edgar","filing":"0001209191-20-056790","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000120919120056790/doc4.xml","form_type":"4"}},{"id":3015661,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-10-03T00:32:15.000Z","date":"2020-10-01","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a 12 month period: 1/12th on November 1, 2020, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":7000,"derivative":{"exercise_price":12.88,"expiration_date":"2030-09-30","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001209191-20-053393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000120919120053393/doc4.xml","form_type":"4"}},{"id":3398181,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2019-10-03T21:26:18.000Z","date":"2019-10-02","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a 12 month period: 1/12th on November 2, 2019, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":7000,"derivative":{"exercise_price":11.21,"expiration_date":"2029-10-01","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001567619-19-019235","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000156761919019235/doc1.xml","form_type":"4"}},{"id":3453034,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-30T23:37:00.000Z","date":"2019-07-29","kind":"purchase","acquired":true,"shares":5137,"price":17.1327,"value":88010.6799,"ownership":{"direct":false,"nature":"By Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.94 to $17.83 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares  purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. The voting members of Vivo Capital IX, LLC are Frank Kung, Albert Cha, Shan Fu, Edgar Engleman and Chen Yu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares, except to the extent of such individual's pecuniary interest in the shares."}],"balance_after":124566,"source":{"system":"sec-edgar","filing":"0001567619-19-015484","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000156761919015484/doc1.xml","form_type":"4"}},{"id":3453033,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-30T23:37:00.000Z","date":"2019-07-29","kind":"purchase","acquired":true,"shares":24730,"price":17.1327,"value":423691.671,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.94 to $17.83 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares  purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Vivo Opportunity Fund, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung, and Michael Chang, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares, except to the extent of such individual's pecuniary interest in the shares."}],"balance_after":1022493,"source":{"system":"sec-edgar","filing":"0001567619-19-015484","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000156761919015484/doc1.xml","form_type":"4"}},{"id":3453032,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-30T23:37:00.000Z","date":"2019-07-26","kind":"purchase","acquired":true,"shares":21942,"price":16.8315,"value":369316.773,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.47 to $16.85 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Vivo Opportunity Fund, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung, and Michael Chang, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares, except to the extent of such individual's pecuniary interest in the shares."}],"balance_after":997763,"source":{"system":"sec-edgar","filing":"0001567619-19-015484","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000156761919015484/doc1.xml","form_type":"4"}},{"id":3453031,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-30T23:37:00.000Z","date":"2019-07-26","kind":"purchase","acquired":true,"shares":4558,"price":16.8315,"value":76717.977,"ownership":{"direct":false,"nature":"By Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.47 to $16.85 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. The voting members of Vivo Capital IX, LLC are Frank Kung, Albert Cha, Shan Fu, Edgar Engleman and Chen Yu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares, except to the extent of such individual's pecuniary interest in the shares."}],"balance_after":119429,"source":{"system":"sec-edgar","filing":"0001567619-19-015484","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000156761919015484/doc1.xml","form_type":"4"}},{"id":3458406,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-19T22:38:57.000Z","date":"2019-07-19","kind":"purchase","acquired":true,"shares":49680,"price":17.8367,"value":886127.256,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price in Column 4 is a weighted average price. These shares were  purchased in multiple transactions at prices ranging from $17.70 to $18.00 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares  purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Opportunity Fund, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung, and Michael Chang, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares, except to the extent of such individual's pecuniary interest in the shares."}],"balance_after":975821,"source":{"system":"sec-edgar","filing":"0001567619-19-015022","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000156761919015022/doc1.xml","form_type":"4"}},{"id":3458405,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-19T22:38:57.000Z","date":"2019-07-19","kind":"purchase","acquired":true,"shares":10320,"price":17.6796,"value":182453.472,"ownership":{"direct":false,"nature":"By Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.56 to $17.70 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares  purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. The voting members of Vivo Capital IX, LLC are Frank Kung, Albert Cha, Shan Fu, Edgar Engleman and Chen Yu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares, except to the extent of such individual's pecuniary interest in the shares."}],"balance_after":114871,"source":{"system":"sec-edgar","filing":"0001567619-19-015022","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000156761919015022/doc1.xml","form_type":"4"}},{"id":3458404,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-19T22:38:57.000Z","date":"2019-07-17","kind":"purchase","acquired":true,"shares":220,"price":16.9273,"value":3724.006,"ownership":{"direct":false,"nature":"By Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.92 to $16.95 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares  purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. The voting members of Vivo Capital IX, LLC are Frank Kung, Albert Cha, Shan Fu, Edgar Engleman and Chen Yu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares, except to the extent of such individual's pecuniary interest in the shares."}],"balance_after":104551,"source":{"system":"sec-edgar","filing":"0001567619-19-015022","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000156761919015022/doc1.xml","form_type":"4"}},{"id":3458403,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-19T22:38:57.000Z","date":"2019-07-17","kind":"purchase","acquired":true,"shares":1060,"price":16.9726,"value":17990.956,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.95 to $17.00 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Opportunity Fund, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung, and Michael Chang, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares, except to the extent of such individual's pecuniary interest in the shares."}],"balance_after":926141,"source":{"system":"sec-edgar","filing":"0001567619-19-015022","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000156761919015022/doc1.xml","form_type":"4"}},{"id":3795837,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2018-10-05T22:05:34.000Z","date":"2018-10-03","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a 12 month period: 1/12th on November 3, 2018, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":7000,"derivative":{"exercise_price":22.65,"expiration_date":"2028-10-02","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001567619-18-003782","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000156761918003782/doc1.xml","form_type":"4"}},{"id":3817906,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-09-12T23:11:55.000Z","date":"2018-09-10","kind":"purchase","acquired":true,"shares":1058824,"price":17,"value":18000008.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"327,339 shares of Common Stock are held of record by Vivo Ventures Fund VI, L.P and 2,398 shares of Common Stock are held of record by Vivo Ventures VI Affiliates Fund, L.P.  Vivo Ventures VI, LLC is the general partner of both Vivo Ventures Fund VI, L.P. and Vivo Ventures VI Affiliates Fund, L.P. The voting members of Vivo Ventures VI, LLC are Frank Kung, Albert Cha, and Edgar Engleman, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of these shares, except to the extent of such individual's pecuniary interests in the shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"925,081 shares of Common Stock are held of record by Vivo Opportunity Fund, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung, and Michael Chang, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares, except to the extent of such individual's pecuniary interest in the shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"104,331 shares of Common Stock are held of record by Vivo Capital Fund IX, L.P.  Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. The voting members of Vivo Capital IX, LLC are Frank Kung, Albert Cha, Shan Fu, Edgar Engleman and Chen Yu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares, except to the extent of such individual's pecuniary interest in the shares."}],"balance_after":1359149,"source":{"system":"sec-edgar","filing":"0001567619-18-002463","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000156761918002463/doc1.xml","form_type":"4"}},{"id":3947657,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-03T17:21:23.000Z","date":"2018-05-01","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this stock option will vest in full on the earlier of (a) May 1, 2019 or (b) the date of the 2019 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date."}],"balance_after":18000,"derivative":{"exercise_price":28.76,"expiration_date":"2028-04-30","underlying":"Common Shares","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-18-027718","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919118027718/doc4.xml","form_type":"4"}},{"id":3994745,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-03-15T18:20:16.000Z","date":"2018-03-14","kind":"grant","acquired":true,"shares":72727,"price":27.5,"value":1999992.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"63,903 of these shares were purchased by Vivo Capital Fund VIII, L.P. (\"VCF\") and 8,824 of these shares were purchased by Vivo Capital Surplus Fund VII, L.P. (\"VCSF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held as follows: 1,800,866 shares are held by VCF and 248,679 shares are held by VCSF. The reporting person is one of the managing members of Vivo Capital VIII, LLC which is the general partner of both VCF and VCSF, and may be deemed to share voting and dispositive power over the shares held by VCF and VCSF. The reporting person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes."}],"balance_after":2049545,"source":{"system":"sec-edgar","filing":"0001209191-18-019938","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919118019938/doc4.xml","form_type":"4"}},{"id":4086239,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-01-29T21:14:57.000Z","date":"2018-01-29","kind":"exercise","acquired":false,"shares":341784,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund III, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is one of the managing members of Vivo Capital VII, LLC (\"Vivo LLC\"), which is the general partner of each of Vivo Capital Fund VIII, L.P. (\"VCF\") and Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":126703},"source":{"system":"sec-edgar","filing":"0001209191-18-005827","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1397906/000120919118005827/doc4.xml","form_type":"4"}},{"id":4086238,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-01-29T21:14:57.000Z","date":"2018-01-29","kind":"exercise","acquired":false,"shares":2475118,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is one of the managing members of Vivo Capital VII, LLC (\"Vivo LLC\"), which is the general partner of each of Vivo Capital Fund VIII, L.P. (\"VCF\") and Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":917559},"source":{"system":"sec-edgar","filing":"0001209191-18-005827","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1397906/000120919118005827/doc4.xml","form_type":"4"}},{"id":4086237,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-01-29T21:14:57.000Z","date":"2018-01-29","kind":"exercise","acquired":false,"shares":874817,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund III, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is one of the managing members of Vivo Capital VII, LLC (\"Vivo LLC\"), which is the general partner of each of Vivo Capital Fund VIII, L.P. (\"VCF\") and Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":324306},"source":{"system":"sec-edgar","filing":"0001209191-18-005827","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1397906/000120919118005827/doc4.xml","form_type":"4"}},{"id":4086236,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-01-29T21:14:57.000Z","date":"2018-01-29","kind":"exercise","acquired":false,"shares":6335215,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is one of the managing members of Vivo Capital VII, LLC (\"Vivo LLC\"), which is the general partner of each of Vivo Capital Fund VIII, L.P. (\"VCF\") and Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2348550},"source":{"system":"sec-edgar","filing":"0001209191-18-005827","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1397906/000120919118005827/doc4.xml","form_type":"4"}},{"id":4086235,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-29T21:14:57.000Z","date":"2018-01-29","kind":"exercise","acquired":true,"shares":126703,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is one of the managing members of Vivo Capital VII, LLC (\"Vivo LLC\"), which is the general partner of each of Vivo Capital Fund VIII, L.P. (\"VCF\") and Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":486695,"source":{"system":"sec-edgar","filing":"0001209191-18-005827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1397906/000120919118005827/doc4.xml","form_type":"4"}},{"id":4086234,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-29T21:14:57.000Z","date":"2018-01-29","kind":"exercise","acquired":true,"shares":917559,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is one of the managing members of Vivo Capital VII, LLC (\"Vivo LLC\"), which is the general partner of each of Vivo Capital Fund VIII, L.P. (\"VCF\") and Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":3524541,"source":{"system":"sec-edgar","filing":"0001209191-18-005827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1397906/000120919118005827/doc4.xml","form_type":"4"}},{"id":4086233,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-29T21:14:57.000Z","date":"2018-01-29","kind":"exercise","acquired":true,"shares":324306,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is one of the managing members of Vivo Capital VII, LLC (\"Vivo LLC\"), which is the general partner of each of Vivo Capital Fund VIII, L.P. (\"VCF\") and Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":359992,"source":{"system":"sec-edgar","filing":"0001209191-18-005827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1397906/000120919118005827/doc4.xml","form_type":"4"}},{"id":4086232,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-29T21:14:57.000Z","date":"2018-01-29","kind":"exercise","acquired":true,"shares":2348550,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is one of the managing members of Vivo Capital VII, LLC (\"Vivo LLC\"), which is the general partner of each of Vivo Capital Fund VIII, L.P. (\"VCF\") and Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":2606982,"source":{"system":"sec-edgar","filing":"0001209191-18-005827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1397906/000120919118005827/doc4.xml","form_type":"4"}},{"id":4086231,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-29T21:14:57.000Z","date":"2018-01-25","kind":"purchase","acquired":true,"shares":35686,"price":17,"value":606662.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund III, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is one of the managing members of Vivo Capital VII, LLC (\"Vivo LLC\"), which is the general partner of each of Vivo Capital Fund VIII, L.P. (\"VCF\") and Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":35686,"source":{"system":"sec-edgar","filing":"0001209191-18-005827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1397906/000120919118005827/doc4.xml","form_type":"4"}},{"id":4086230,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-29T21:14:57.000Z","date":"2018-01-25","kind":"purchase","acquired":true,"shares":258432,"price":17,"value":4393344.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is one of the managing members of Vivo Capital VII, LLC (\"Vivo LLC\"), which is the general partner of each of Vivo Capital Fund VIII, L.P. (\"VCF\") and Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":258432,"source":{"system":"sec-edgar","filing":"0001209191-18-005827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397906/000120919118005827/doc4.xml","form_type":"4"}},{"id":4199006,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-09-29T23:15:06.000Z","date":"2017-09-27","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a 12 month period: 1/12th on October 27, 2017, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":6000,"derivative":{"exercise_price":6.71,"expiration_date":"2027-09-26","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001140361-17-037013","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000114036117037013/doc1.xml","form_type":"4"}},{"id":4328409,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Shares","published_at":"2017-05-09T16:45:55.000Z","date":"2017-05-09","kind":"exercise","acquired":false,"shares":1506818,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common shares, each Series A Preferred Share automatically converted into one common share of the Issuer.  The Series A Preferred Shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common shares, each Series A Preferred Share automatically converted into one common share of the Issuer.  The Series A Preferred Shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common shares, each Series A Preferred Share automatically converted into one common share of the Issuer.  The Series A Preferred Shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held as follows: 1,323,990 shares are held by Vivo Capital Fund VIII, L.P. (\"VCF\") and 182,828 shares are held by Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\"). The reporting person is one of the managing members of Vivo Capital VIII, LLC which is the general partner of both VCF and VCSF, and may be deemed to share voting and dispositive power over the shares held by VCF and VCSF. The reporting person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":1506818},"source":{"system":"sec-edgar","filing":"0001209191-17-030977","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919117030977/doc4.xml","form_type":"4"}},{"id":4328408,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2017-05-09T16:45:55.000Z","date":"2017-05-09","kind":"purchase","acquired":true,"shares":470000,"price":17,"value":7990000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 412,973 shares are held by VCF and 57,027 shares are held by VCSF. The reporting person is one of the managing members of Vivo Capital VIII, LLC which is the general partner of both VCF and VCSF, and may be deemed to share voting and dispositive power over the shares held by VCF and VCSF. The reporting person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes."}],"balance_after":1976818,"source":{"system":"sec-edgar","filing":"0001209191-17-030977","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919117030977/doc4.xml","form_type":"4"}},{"id":4328407,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2017-05-09T16:45:55.000Z","date":"2017-05-09","kind":"exercise","acquired":true,"shares":1506818,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares received upon conversion of Series A Preferred Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares received upon conversion of Series A Preferred Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held as follows: 1,323,990 shares are held by Vivo Capital Fund VIII, L.P. (\"VCF\") and 182,828 shares are held by Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\"). The reporting person is one of the managing members of Vivo Capital VIII, LLC which is the general partner of both VCF and VCSF, and may be deemed to share voting and dispositive power over the shares held by VCF and VCSF. The reporting person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes."}],"balance_after":1506818,"source":{"system":"sec-edgar","filing":"0001209191-17-030977","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919117030977/doc4.xml","form_type":"4"}},{"id":4371365,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":58525,"kind":"person","name":"Cha Albert","position":1,"cik":"0001397906","reported_name":"Cha Albert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-03-27T23:05:42.000Z","date":"2017-03-23","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a 3 year period: 1/36th on December 21, 2016, after which 1/36th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":12000,"derivative":{"exercise_price":7.88,"expiration_date":"2027-03-22","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001140361-17-013498","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000114036117013498/doc1.xml","form_type":"4"}}]}